medigraphic.com

2020, Number 5

<< Back Next >>

Rev Fac Med UNAM 2020; 63 (5)

Physiology of Hemostasis and its Alteration by Coagulopathy in COVID-19

González-Villalva A, de la Peña-Díaz A, Rojas-Lemus M, López-Valdez N, Ustarroz-Cano M, García-Peláez I, Bizarro-Nevares P, Fortoul TI

Language: Spanish
References: 63
Page: 45-57
PDF size: 568.13 Kb.


ABSTRACT

COVID-19 global pandemic caused by Sars-CoV-2 virus, has worried to health care providers due to the high mortality rate related to coagulopathy in many patients. COVID-19 coagulopathy is mainly thrombotic, first locally in lungs but later on it becomes micro and macrovascular systemic coagulopathy. It has been associated to endothelial damage, inflammation, neutrophil-extracellular traps, monocyte and macrophage activation, cytokines storm that induce a vicious cycle of thrombosis and inflammation. The increased levels of prothrombotic factors as tissue factor, Von Willebrand factor, fibrinogen, VIII factor and the decreased levels of antithrombotic factos, such as: antithrombin and Protein S have been reported in COVID-19 patients. Insufficiency of fibrinolysis because of the increased levels of PAI-1 (plasminogen activator inhibitor 1) have been reported also. During this disease there are intraalveolar fibrin deposits that needs to be degraded. Fibrinolysis of thrombus and fibrin intraalveolar degradation are responsible for the high increase of D-dimers levels that are an important predictor of severity of the disease. In this report, the physiology of hemostasis, thromboinflamation secondary to Sars-CoV-2 infection are reviewed, as well as the clinical evidence and the physiopathology of COVID-19 coagulopathy from the basic sciences point of view.


REFERENCES

  1. De la Peña Díaz A, Flores García M, Garza Deschamps F, González Villalva A. Capítulo 13. Hemostasia. En: Fortoul van der Goes Teresa I. Guía de Biología celular e Histología médica. Editorial Intersistemas. Primera edición. México; 2011. p.176-87.

  2. Zaidi A, Green L. Physiology of haemostasis. Anaesth Intensive Care Med. 2019;20(3):152-158.

  3. González-Villalva A, Bizarro-Nevares P, Rojas-Lemus M, López-Valdéz Nelly, Ustarroz-Cano M, Barbosa-Barrón F, García-Gil B, Albarrán Alonso JC, Fortoul van der Goes T. El megacariocito: una célula muy original. Rev Fac Med (UNAM). 2019;62(1):6-18.

  4. González Villalva Adriana. Capítulo 9. Sangre. En: Fortoul Teresa. Histología y Biología Celular. Tercera edición. México: Ed. McGraw-Hill Interamericana; 2017. p. 157-64.

  5. Martínez-Murillo C. Mecanismos de activación de la coagulación. Rev Med Inst Mex Seguro Soc. 2006;44(Supl 2):51-8.

  6. Gremmel T, Frelinger III AL, Michelson AD. Platelet physiology. Semin Thromb Hemost. 2016;42:191-204.

  7. Pryzdial E, Lee F, Lin B, Carter R, Tegegn T y Belletrutti. Blood coagulation dissected. Transfus Apher Sci. 2018;57:449-57.

  8. Grover SP and Mackman N. Tissue Factor. An Essential mediator of hemostasis and trigger of thrombosis. Arterioescler Thromb Vasc Biol. 2018;38(4):709-25.

  9. Maas C, Renne T. Coagulation factor XII in thrombosis and inflammation. Blood. 2018;131(17):1903-9.

  10. Longstaff C. Measuring fibrinolysis: from research to routine diagnostic assays. J Thromb Haemost. 2018;16:652-62.

  11. Zhu N, Zhang D, Wang W, Xingwang L, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33.

  12. Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270-3.

  13. Chan J, Kok K, Zhu Z, Chu H, To KKW, Yuan S, Yuen KY. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221-36.

  14. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181(2):281-92.

  15. Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, Guo L, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020;11:1620. https://doi.org/10.1038/s41467- 020-15562-9.

  16. Bertram S, Heurich A, Lavender H, Gierer S, Danisch S, Perin P, et al. Influenza and SARS-Coronavirus Activating Proteases TMPRSS2 and HAT Are Expressed at Multiple Sites in Human Respiratory and Gastrointestinal Tracts. PLOS ONE 2012;7(4):e35876. https://doi.org/10.1371/ journal.pone.0035876.

  17. Hoffmann M, Kleine H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-280.

  18. Altmann D, Boyton R. Sars-Cov2 T cell immunity: specificity, function, durability and role in protection. Sci Immunol. 2020;5(49):eabd6160. DOI: 10.1126/sciimmunol.abd6160

  19. Tay, MZ, Poh CM, Rénia L, MacAry P and Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 20;363-74.

  20. Lombardi A, Trombetta E, Cattaneo A, Castelli V, Palomba E, Tirone M, et al. MedRxiv Preprint. doi: https://doi. org/10.1101/2020.05.01.20087080

  21. Merad M, Martin J. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20:355-62.

  22. Iba T, Levy JH, Connors JM, Warkentin T, Thachil J, Levi M. The unique characteristics of COVID-19 coagulopathy. Crit Care. 2020;24:360. https://doi.org/10.1186/ s13054-020-03077-0

  23. Yang Y, Chenguang S, Jinxiu L, Jing Y, Minghui Y, Fuxiang W, et al. Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-CoV-2 infection is associated with disease severity and fatal outcome. medRxiv. 2020;20029975. Preprint doi: https://doi.org/10.1101/2020.03.02.20029975

  24. Barnes BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, Cools-Lartigue J, Crawford JM, et al. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. J Exp Med. 2020;217(6):e20200652. doi: 10.1084/ jem.20200652.

  25. Tomar B, Anders HJ, Desai J, Mulay SR. Neutrophils and Neutrophil Extracellular Traps Drive Necroinflammation in COVID-19. Cells. 2020;9(6):E1383. doi: 10.3390/ cells9061383.

  26. Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, et al. Neutrophil extracellular traps in COVID-19. JCI Insight. 2020;5(11):138999. doi: 10.1172/jci.insight.138999.

  27. Middleton E, He XA, Denorme F, Campbell RA, David N, Salvatore SP, et al. Neutrophil Extracellular Traps (NETs) Contribute to Immunothrombosis in COVID-19 Acute Respiratory Distress Syndrome. Blood. 2020. doi: https://doi.org/10.1182/blood.2020007008

  28. Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145-7.

  29. Helms J, Tacquard C, Severac , Leonard-Lorant I, Ohana M, Delabranche X, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46:1089-98.

  30. Fraissé M, Logre E, Pajot O, Mentec H, Plantefève G, Contou D. Thrombotic and hemorrhagic events in critically ill COVID-19 patients: a French monocenter retrospective study. Crit Care. 2020;24(1):275. doi:10.1186/ s13054-020-03025-y

  31. Llitjos J‐F, Leclerc M, Chochois C, Monsallier JM, Ramakers M, Auvray M and Merouani K. High incidence of venous thromboembolic events in anticoagulated severe COVID‐19 patients. J Thromb Haemost. 2020;18:1743-6.

  32. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger E, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. Physiol Rev. 2020;100(3):1065-75.

  33. Marini JJ, Gattinoni L. Management of COVID-19 respiratory distress. JAMA. 2020;323(22):2329-30.

  34. Pernazza A, Mancini M, Rullo E, Bassi M, De Giacomo T, Rocca CD, d’Amati G. Early histologic findings of pulmonary SARS-CoV-2 infection detected in a surgical specimen [citado 22 de mayo de 2020]. Virchows Arch. 2020.

  35. Bavishi C, Bonow RO, Trivedi V, Abbott JD, Messerli FH, Bhatt DL. Acute myocardial injury in patients hospitalized with COVID-19 infection: A review. Prog Cardiovasc Dis. 2020. doi:10.1016/j.pcad.2020.05.013

  36. Divani, AA, Andalib S, Di Napoli M, Lattanzi S, Hussain M.S, Biller J, et al. Coronavirus disease 2019 and stroke: clinical manifestations and pathophysiological insights. J Stroke Cerebrovasc Dis. 2020;104941. https:// doi.org/10.1016/j.jstrokecerebrovasdis.2020.104941

  37. Poillon G, Obadia M, Perrin M, Savatovsky J, Lecler A. Cerebral venous thrombosis associated with COVID-19 infection: Causality or coincidence? J Neuroradiol. 2020;S0150- 9861(20)30167-X. doi:10.1016/j.neurad.2020.05.003

  38. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020:e201127. doi: 10.1001/jamaneurol.2020.1127.

  39. Wichmann D, Sperhake JP, Lütgehetmann M, Steurer S, Edler C, Heinemann A, et al. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19. Ann Intern Med. 2020;M20-2003. doi:10.7326/M20-2003

  40. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18(6):1421-4.

  41. Davoodi L, Jafarpour H, Taghavi M, Razavi A. COVID-19 Presented With Deep Vein Thrombosis: An Unusual Presenting. J Investig Med High Impact Case Rep. 2020;8: 2324709620931239. doi:10.1177/2324709620931239

  42. Kashi M, Jacquin A, Dakhil B, et al. Severe arterial thrombosis associated with Covid-19 infection. Thromb Res. 2020;192:75-7.

  43. Vulliamy P, Jacob S, Davenport RA. Acute aorto-iliac and mesenteric arterial thromboses as presenting features of COVID-19. Br J Haematol. 2020;189(6):1053-4.

  44. Mestres G, Puigmacià R, Blanco C, Yugueros X, Esturrica M, Riambau V. Risk of peripheral arterial thrombosis in COVID-19. J Vasc Surg. 2020;S0741-5214(20)31074-0. doi:10.1016/j.jvs.2020.04.477 Epub May 7 2020.

  45. Di Mascio D, Khalil A, Saccone G, Rizzo G, Buca D, Liberati M, et al. Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2020;25:100107. https://doi.org/10.1016/j. ajogmf.2020.100107

  46. Shanes ED, Mithal LB, Otero S, Azad HA, Miller ES, Goldstein JA. Placental Pathology in COVID-19. Am J Clin Pathol. 2020;8;154(1):23-32.

  47. Mulvey JJ, Magro CM, Ma LX, Nuovo GJ, Baergen RN. Analysis of complement deposition and viral RNA in placentas of COVID-19 patients. Ann Diagn Pathol. 2020; 46:151530.

  48. Chen L, Hao G. The role of angiotensin-converting enzyme 2 in coronaviruses/influenza viruses and cardiovascular disease. Cardiovasc Res. 2020; 0, 1-5. doi:10.1093/ cvr/cvaa093

  49. Wang J, Saguner AM, An J, Ning Y, Yan Y, Li G. Dysfunctional coagulation in COVID-19: From Cell to bedside. Adv Ther. 2020;37:3033-9. https://doi.org/10.1007/ s12325-020-01399-7

  50. Teuwen L, Geldhof V, Pasut A. Carmeliet P. COVID-19: the vasculature unleashed. Nature Reviews in Immunology. 2020;448. https://doi.org/10.1038/s41577-020-0356-8

  51. Sardu C, Gambardella J, Morelli MB, Wang X, Marfella R, Santulli G. Is COVID-19 an Endothelial Disease? Clinical and Basic Evidence. Preprints 2020, 2020040204. doi: 10.20944/preprints202004.0204.v1

  52. Manne BK, Denorme F, Middleton EA, Portier I, Rowley JW, Stubben CJ, et al. Platelet Gene Expression and Function in COVID-19 Patients. Blood 2020 blood.2020007214. doi: https://doi.org/10.1182/blood.2020007214

  53. Betsy J. Barnes, Jose M. Adrover, Amelia Baxter-Stoltzfus, et al. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. J Exp Med. 2020 Jun 1;217(6):e20200652.

  54. Becker R. COVID-19 update: Covid-19-associated coagulopathy. J Thromb Thrombolysis. 2020;50:54-67.

  55. Whyte CS, Morrow GB, Mitchell J, Chowdary P and Mutch NJ. Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19. J Thromb Haemost. 2020;18:1548-55.

  56. Gupta N, You-Yang Z, Evans C. The stimulation of thrombosis by hypoxia. Thromb Res. 2019;181:77-83.

  57. Panigada M, Bottino N, Tagliabue P, Grasselli G, Novembrino C, Chantarangkul V, et al. Hypercoagulability of COVID‐19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost. 2020;18:1738-42.

  58. Thachil J, Cushman M, Srivastava A. A proposal for staging COVID-19 coagulopathy. Res Pract Thromb Haemost. 2020;4:731-6.

  59. Hong-Long Ji, Runzhen Zhao, Sadis Matalon, Michael A. Matthay. Elevated Plasmin(ogen) as a Common Risk Factor for COVID-19 Susceptibility. Physiol Rev. 2020 Jul 1;100(3):1065-75.

  60. Lippi G, Favaloro EJ. D-dimer is Associated with Severity of Coronavirus Disease 2019: A Pooled Analysis. Thromb Haemost. 2020;20(05):876-8.

  61. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23): 2033-40.

  62. Fox SE, Akmatbekov A, Harbert JL, Li G, Brown JQ, VanderHeide RS. Pulmonary and cardiac pathology in Covid-19: the first autopsy series from New Orleans. medRxiv. Preprint. https ://doi.org/10.1101/2020.04.06.20050575

  63. Thachil J. The versatile heparin in COVID-19. J Thromb Haemost. 18:1020-2.




2020     |     www.medigraphic.com